Suboptimal aminoglycoside dosing in critically ill patients.
about
Therapeutic drug monitoring of amikacin in septic patients.Revisiting the loading dose of amikacin for patients with severe sepsis and septic shockOutcomes in patients with gram-negative sepsis treated with gentamicinVancomycin dosing assessment in intensive care unit patients based on a population pharmacokinetic/pharmacodynamic simulation.Is the standard dose of amoxicillin-clavulanic acid sufficient?Predictive performance of gentamicin dosing nomograms.Amikacin monotherapy for sepsis caused by panresistant Pseudomonas aeruginosa.Treatment of carbapenem-resistant Klebsiella pneumoniae: the state of the art.Tobramycin disposition in ICU patients receiving a once daily regimen: population approach and dosage simulations.Propensity-based study of aminoglycoside nephrotoxicity in patients with severe sepsis or septic shockHow do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients?Correlations between Income inequality and antimicrobial resistance.Once-daily amikacin dosing in burn patients treated with continuous venovenous hemofiltration.Therapeutic drug monitoring of antimicrobials.Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing.Empiric antimicrobial therapy in severe sepsis and septic shock: optimizing pathogen clearancePlasma Peak and Trough Gentamicin Concentrations in Hospitalized Horses Receiving Intravenously Administered Gentamicin.Bench-to-bedside review: Appropriate antibiotic therapy in severe sepsis and septic shock--does the dose matter?Once-daily gentamicin dosing in children with febrile neutropenia resulting from antineoplastic therapy.Can Pharmacokinetic and Pharmacodynamic Principles Be Applied to the Treatment of Multidrug-Resistant Acinetobacter?Continuing education: alternative approaches to optimizing antimicrobial pharmacodynamics in critically ill patients.Pharmacological considerations for the proper clinical use of aminoglycosides.Aminoglycosides in septic shock: an overview, with specific consideration given to their nephrotoxic risk.Optimal dosing of antibiotics in critically ill patients by using continuous/extended infusions: a systematic review and meta-analysis.Therapeutic drug monitoring of anti-infective agents in critically ill patients.Population Pharmacokinetic Characteristics of Amikacin in Suspected Cases of Neonatal Sepsis in a Low-Resource African Setting: A Prospective Nonrandomized Single-Site Study.Reduced Chance of Hearing Loss Associated with Therapeutic Drug Monitoring of Aminoglycosides in the Treatment of Multidrug-Resistant TuberculosisPopulation pharmacokinetic modelling, Monte Carlo simulation and semi-mechanistic pharmacodynamic modelling as tools to personalize gentamicin therapy.Successful treatment of a Carbapenem-resistant Klebsiella pneumoniae carrying bla OXA-48 , bla VIM-2 , bla CMY-2 and bla SHV- with high dose combination of imipenem and amikacinAminoglycosides against carbapenem-resistant Enterobacteriaceae in the critically ill: the pitfalls of aminoglycoside susceptibility.A high-dose aminoglycoside regimen combined with renal replacement therapy for the treatment of MDR pathogens: a proof-of-concept study.Early and adequate antibiotic therapy in the treatment of severe sepsis and septic shock.Clinical experience with aminoglycosides in dialysis-dependent patients: risk factors for mortality and reassessment of current dosing practices.The challenge of curbing aminoglycoside resistance: can antimicrobial stewardship programs play a critical role?Comment on: Mortality due to blaKPC Klebsiella pneumoniae bacteraemia.
P2860
Q33754166-76BB8423-AD6C-45D1-812E-E2351C0CF7D8Q33919190-A4DDFA2A-675C-4D6B-8751-AD48D10DC6B4Q33949330-FE500B4B-53D3-4E7A-AEE4-C084A0A2E8E0Q34026240-3A831EE6-4AD7-466E-BCA0-861E9B70EE19Q34030839-78085077-7823-4281-9C39-D84328D44289Q34075284-ED2A5358-9CEA-4D3D-9CE6-0EFE560D1EEEQ34290150-2F6FCEBB-D229-4FA7-9B92-A69C088C910DQ34327857-1AF04F54-96F1-41FA-8959-BD3C178887A8Q34476089-FD6AB94C-AD67-4E48-AAE9-649750BA412AQ34597640-AD72BF5B-D466-418D-B4BA-3E76F8825081Q34894900-B43072E9-169D-43B4-97A2-7FB24C6F11FEQ34979717-EBEE94E8-7013-4018-A9CD-3151BE0A72CDQ35270646-D5980990-8669-466D-B002-24C9139F2ADAQ35640430-2D8E750B-3E94-4337-8EB7-1715F6895864Q36083619-757D7E25-1BCF-4487-97B2-557A30755A47Q36089167-41CC5B08-047F-434F-923F-EA214BC3EBC4Q36975688-86F1C1DD-871D-4643-BAA8-3FE2B04617AFQ37516599-224F5BF0-A90F-4485-AD96-5804F294A585Q37661501-60D540D9-125F-44C2-8BF9-DA7DFB0D9F7AQ37838126-75A69BEF-77C2-41BC-8D0C-E17A428FE640Q37867260-F6D8F56E-8604-4E49-AA35-E79DE4EBD93AQ37956403-6A43C562-9D1F-4B01-938E-5D48ABF8C1B0Q38090988-BCEC3396-2CB2-4C1F-AB63-0E0447D87D24Q38167345-5169A66C-E01E-407A-B01D-666BC30E150BQ38790740-576CC62E-22B3-458F-9228-A1099FD54793Q38873556-B594B519-65A3-4314-BCA4-304550EAB3F7Q39030684-5B9096C7-A5D7-45FA-9827-6D709A37F531Q39071799-BC0E9D18-6094-4F9E-AF40-2419C95348D9Q39325205-81F129FE-9A2F-4C83-9B9A-EF8F72CDB6FEQ40265579-FAB7A920-5A99-4FE4-9CEE-C938075D54F1Q40809870-4EBE17B0-B498-4B71-986B-8D54F45E365AQ44658786-F170E80B-27AD-4649-ABB5-C451FB856966Q45734205-DF56794B-C789-4CEC-A2A4-FE320A86E04CQ47939381-D8865625-51D6-464A-BDB9-093C4BC47C4EQ53793889-BB0C7A15-6764-49C9-9FBF-058367679CC3
P2860
Suboptimal aminoglycoside dosing in critically ill patients.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Suboptimal aminoglycoside dosing in critically ill patients.
@en
Suboptimal aminoglycoside dosing in critically ill patients.
@nl
type
label
Suboptimal aminoglycoside dosing in critically ill patients.
@en
Suboptimal aminoglycoside dosing in critically ill patients.
@nl
prefLabel
Suboptimal aminoglycoside dosing in critically ill patients.
@en
Suboptimal aminoglycoside dosing in critically ill patients.
@nl
P2093
P1476
Suboptimal aminoglycoside dosing in critically ill patients.
@en
P2093
Blair Capitano
Howard Lee
Kristin L Bigos
Randall Smith
Rhonda S Rea
Robert Bies
P304
P356
10.1097/FTD.0B013E31818B6B2F
P577
2008-12-01T00:00:00Z